GLP-2T (Tirzepatide) is an advanced peptide developed to support weight management and overall metabolic health by functioning as a dual—or multi—receptor agonist. It primarily targets the receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two important hormones that help regulate appetite, blood sugar, and energy balance. By activating these pathways, Tirzepatide can reduce hunger, slow gastric emptying, and increase feelings of fullness, leading to lower food intake and improved blood sugar control. Its ability to act on multiple hormonal systems makes it a promising option for individuals dealing with obesity and type 2 diabetes.

​

Tirzepatide works by increasing insulin release when blood glucose levels are elevated, while also suppressing glucagon secretion to help bring blood sugar down. Activation of both GIP and GLP-1 receptors further enhances insulin sensitivity and supports fat metabolism, contributing to weight loss and improved metabolic flexibility. Together, these effects lead to better glucose regulation, decreased visceral fat, and more balanced energy utilization. Due to its comprehensive mechanism, Tirzepatide is viewed as a next-generation approach for metabolic disorders, offering wide-ranging benefits for weight control and long-term metabolic health.